Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24?900 Survivors.

Milano MT, Dinh PC, Yang H, Zaid MA, Fossa SD, Feldman DR, Monahan PO, Travis LB, Fung C. Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24?900 Survivors. JNCI cancer spectrum. 2020 Jun 1; 4(3):pkaa017.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


BACKGROUND: No large US population-based study focusing on recent decades, to our knowledge, has comprehensively examined risks of second malignant solid and hematological neoplasms (solid-SMN and heme-SMN) after testicular cancer (TC), taking into account initial therapy and histological type. METHODS: Standardized incidence ratios (SIR) vs the general population and 95% confidence intervals (CI) for solid-SMN and heme-SMN were calculated for 24?900 TC survivors (TCS) reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results registries (1973-2014). All statistical tests were two-sided. RESULTS: The median age at TC diagnosis was 33?years. Initial management comprised chemotherapy (n? = 6340), radiotherapy (n? = 9058), or surgery alone (n? = 8995). During 372 709 person-years of follow-up (mean? = 15?years), 1625 TCS developed solid-SMN and 228 (107 lymphomas, 92 leukemias, 29 plasma cell dyscrasias) developed heme-SMN. Solid-SMN risk was increased 1.06-fold (95% CI? = 1.01 to 1.12), with elevated risks following radiotherapy (SIR? = 1.13, 95% CI? = 1.06 to 1.21) and chemotherapy (SIR? = 1.36, 95% CI? = 1.12 to 1.41) but not surgery alone (SIR? = 0.83, 95% CI? = 0.75 to 0.92). Corresponding risks for seminoma were 1.13 (95% CI? = 1.06 to 1.21), 1.28 (95% CI? = 1.02 to 1.58), and 0.87 (95% CI? = 0.74 to 1.01) and for nonseminoma were 1.05 (95% CI? = 0.67 to 1.56), 1.25 (95% CI? = 1.08 to 1.43), and 0.80 (95% CI? = 0.70 to 0.92), respectively. Thirty-year cumulative incidences of solid-SMN after radiotherapy, chemotherapy, and surgery alone were 16.9% (95% CI? = 15.7% to 18.1%), 10.1% (95% CI? = 8.8% to 11.5%), and 8.8% (95% CI? = 7.8% to 9.9%), respectively (? < .0001). Increased leukemia risks after chemotherapy (SIR? = 2.68, 95% CI? = 1.70 to 4.01) were driven by statistically significant sevenfold excesses of acute myeloid leukemia 1 to 10?years after TC diagnosis. Risks for lymphoma and plasma cell dyscrasias were not elevated. CONCLUSIONS: We report statistically significant excesses of solid-SMN affecting 1 in 6 TCS 30?years after radiotherapy, and 2.7-fold risks of leukemias after chemotherapy, mostly acute myeloid leukemia. Efforts to minimize chemotherapy and radiotherapy exposures for TC should continue. TCS should be counseled about cancer prevention and screening.

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.